As a promising HER2-targeted agent, adding pyrotinib to trastuzumab and neoadjuvant chemotherapy further improved the pathological complete response (pCR) rate up to 69.81% in patients with early or locally advanced breast cancer in a phase II NeoATP trial (12). The gene discussed is ERBB2; the disease is breast cancer.